Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 5/20 | 0.35 |
| ▸ | DNM2 | P50570 | 7/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18415054 | 0.97 | CNR2 (0.36) | CNR2GPR84CNR1DNM2KCNH2 | |
| SCHEMBL20852881 | 0.79 | CNR2 (0.42) | CNR2GPR84CNR1DNM2GAA | |
| SCHEMBL22487744 | 0.77 | CNR2 (0.38) | CNR2GPR84CNR1DNM2GAA | |
| SCHEMBL22375298 | 0.76 | CNR2 (0.41) | CNR2GPR84CNR1DNM2GAA | |
| SCHEMBL18415095 | 0.74 | CNR2 (0.34) | CNR2CNR1DNM2GAAHTT | |
| SCHEMBL26326025 | 0.73 | KCNH2 (0.41) | CNR2CNR1KCNH2SMN1; SMN2 | |
| SCHEMBL22375312 | 0.73 | KCNH2 (0.41) | CNR2CNR1KCNH2SMN1; SMN2 | |
| SCHEMBL26850422 | 0.73 | KCNH2 (0.34) | CNR2GPR84CNR1KCNH2 | |
| SCHEMBL12539085 | 0.72 | KCNH2 (0.50) | GPR84DNM2KCNH2 | |
| SCHEMBL18856538 | 0.71 | CYP1A2 (0.39) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | CNR2 1173/4885GPR84 1378/4885CNR1 1937/4885 |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | CNR2 1173/4885GPR84 1378/4885CNR1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.